# Bolt

Source: https://en.bioecon.ru/companies/bolt-threads/
Updated: 2026-06-24

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | The company relies on external capital and collaborations; as of June 30, 2026, it held $18.1 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into the first quarter of 2027. | https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/bolt-20251231.htm, https://www.sec.gov/Archives/edgar/data/1641281/000119312526186950/bolt_2026_annual_report_.pdf, https://www.sec.gov/Archives/edgar/data/1641281/000119312526344597/bolt-20260630.htm, https://www.stocktitan.net/sec-filings/BOLT/10-q-bolt-biotherapeutics-inc-quarterly-earnings-report-6d2fdb2a42a6.html |
| Capacity | The company does not own or operate any manufacturing facilities and relies on third-party contract development and manufacturing organizations (CDMOs). | https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/bolt-20251231.htm, https://www.sec.gov/Archives/edgar/data/1641281/000119312526186950/bolt_2026_annual_report_.pdf |
| Regulatory approval | The company's product candidates, such as BDC-4182, require FDA approval via a Biologics License Application (BLA) before they can be marketed in the United States. | https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/bolt-20251231.htm, https://www.sec.gov/Archives/edgar/data/1641281/000119312526186950/bolt_2026_annual_report_.pdf |
| Production site | The company does not own manufacturing facilities and relies on third-party CDMOs; its corporate office and laboratory space is in Redwood City, California. | https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/bolt-20251231.htm, https://www.sec.gov/Archives/edgar/data/1641281/000119312526344597/bolt-20260630.htm |
| Headcount | A major October 2025 restructuring cut headcount by approximately 50%. | https://www.stocktitan.net/sec-filings/BOLT/10-q-bolt-biotherapeutics-inc-quarterly-earnings-report-6d2fdb2a42a6.html |
| Revenue | Total collaboration revenue was $5,000 for the second quarter of 2026 and $18,000 for the six months ended June 30, 2026. | https://boltbiotherapeutics.gcs-web.com/news-releases/news-release-details/bolt-biotherapeutics-reports-second-quarter-2026-financial, https://www.sec.gov/Archives/edgar/data/1641281/000119312526344597/bolt-20260630.htm, https://www.stocktitan.net/sec-filings/BOLT/10-q-bolt-biotherapeutics-inc-quarterly-earnings-report-6d2fdb2a42a6.html |

Independent sources: sec.gov, stocktitan.net

## Technologies

- [Bio-camouflage & bio-armor materials](https://en.bioecon.ru/technology/bio-camouflage-armor-materials/)
- [Biotech in the textile industry](https://en.bioecon.ru/technology/biotech-textile-industry/)
- [Natural fibers & bio-textiles](https://en.bioecon.ru/technology/natural-fibers-bio-textiles/)
- [Recombinant spider silk & engineered protein fibers](https://en.bioecon.ru/technology/recombinant-spider-silk/)
- [Silk fibroin (recombinant, biomaterials)](https://en.bioecon.ru/technology/silk-fibroin-recombinant-biomaterials/)